Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
0.560
-0.023 (-3.86%)
Mar 6, 2026, 10:05 AM EST - Market open
Decoy Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | - | - | - | - | 1.84 | 5.23 | |
| Revenue Growth (YoY) | - | - | - | - | -64.84% | 51.03% | |
| Cost of Revenue | - | - | - | - | 8.55 | 6.91 | |
| Gross Profit | - | - | - | - | -6.71 | -1.68 | |
| Selling, General & Admin | 5.14 | 4.96 | 5.72 | 7.14 | 6.1 | 6.11 | |
| Research & Development | 0.43 | 0.77 | 7.17 | 15.84 | - | - | |
| Operating Expenses | 5.57 | 5.73 | 12.89 | 22.98 | 6.1 | 6.11 | |
| Operating Income | -5.57 | -5.73 | -12.89 | -22.98 | -12.81 | -7.79 | |
| Interest & Investment Income | 0.06 | 0.16 | 0.35 | 0.22 | - | - | |
| Other Non Operating Income (Expenses) | - | - | - | 0.01 | 0.04 | 0.43 | |
| EBT Excluding Unusual Items | -5.5 | -5.58 | -12.54 | -22.74 | -12.77 | -7.35 | |
| Impairment of Goodwill | - | - | - | -8.87 | - | - | |
| Pretax Income | -5 | -5.58 | -12.54 | -31.61 | -12.77 | -7.35 | |
| Net Income | -5 | -5.58 | -12.54 | -31.61 | -12.77 | -7.35 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 0.4 | |
| Net Income to Common | -5 | -5.58 | -12.54 | -31.61 | -12.77 | -7.75 | |
| Free Cash Flow | -4.43 | -4.53 | -12.85 | -17.6 | -10.2 | -10.31 | |
| Gross Margin | - | - | - | - | - | -32.11% | |
| Operating Margin | - | - | - | - | -696.27% | -148.78% | |
| Profit Margin | - | - | - | - | -693.84% | -148.06% | |
| Free Cash Flow Margin | - | - | - | - | -554.29% | -197.08% | |
| EBITDA | -5.56 | -5.73 | -12.88 | -22.97 | -12.79 | -7.77 | |
| EBITDA Margin | - | - | - | - | - | -148.44% | |
| D&A For EBITDA | 0 | 0 | 0.01 | 0.01 | 0.02 | 0.02 | |
| EBIT | -5.57 | -5.73 | -12.89 | -22.98 | -12.81 | -7.79 | |
| EBIT Margin | - | - | - | - | - | -148.78% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.